Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2025-12-24 @ 3:07 PM
NCT ID:
NCT00003292
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically proven recurrent or unresectable:
* Malignant meningioma
* Intracranial hemangiopericytoma
* Primary central nervous system sarcoma, including:
* Fibrosarcoma
* Rhabdomyosarcoma
* Chondrosarcoma
* Leiomyosarcoma
* Measurable or evaluable disease on CT or MRI scan
* Persistent disease following biopsy or incomplete resection OR
* Recurrent disease following complete resection
* No benign meningioma
* No prior or current systemic sarcoma
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* SWOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC at least 3,000/mm\^3
* Absolute granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Not specified
Renal:
* Creatinine no greater than 2.0 mg/dL
Cardiovascular:
* No myocardial infarction within the past 3 months
* No active angina
* No unstable heart rhythms
* No congestive heart failure
Other:
* HIV negative
* No allergy to study drugs
* No serious concurrent medical or psychiatric illness
* No uncontrolled peptic ulcer disease
* No prior malignancy within past 5 years except adequately treated:
* Basal or squamous cell carcinoma of the skin
* Carcinoma in situ of the cervix
* Not pregnant or nursing
* Effective contraception required of fertile patients
PRIOR CONCURRENT THERAPY:
* Recovered from toxic effects of prior therapy and/or from postoperative complications
Biologic therapy:
* Not specified
Chemotherapy:
* No prior ifosfamide
* No other concurrent chemotherapy
Endocrine therapy:
* No concurrent hormonal therapy (except estrogen replacement therapy)
* Corticosteroids allowed if dose is stable or decreasing
Radiotherapy:
* At least 4 weeks since prior radiotherapy
* Progressive disease following radiation required
* No concurrent radiotherapy
Surgery:
* See Disease Characteristics
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00003292
Study Brief:
Protocol Section:
NCT00003292